The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) of Université de Montréal will attend the 23rd Annual International Partnering Conference BIO-Europe. This conference is being held from November 6 to November 8, 2017 at the CityCube in Berlin, Germany.
IRICoR will be participating for the seventh consecutive year in this industry event that aims to create business opportunities between life science players from around the world. It is also an opportunity for companies and institutions to develop partnerships of interest with complementary organizations, notably by presenting projects and networking opportunities.
If you would like to meet with IRICoR at Bio Europe, please contact Steven Klein, PhD, MBA, Vice President, Business Development, who will represent IRICoR at this event:
- By email :email@example.com
- By phone : 514.343.6647
For more information about BIO-Europe 2017 click here : BIO-Europe 2017 (site en anglais seulement).
About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)
As Université de Montréal’s drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: www.iricor.ca